Rachel Y Gao1,2, Meng Wang1,3, Qihui Liu1, Dechun Feng4, Yankai Wen3, Yang Xia5, Sean P Colgan2, Holger K Eltzschig3, Cynthia Ju1,3. 1. Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO. 2. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. 3. Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX. 4. Laboratory of Liver Disease, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD. 5. Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX.
Abstract
BACKGROUND AND AIMS: Acetaminophen (APAP) overdose represents the most frequent cause of acute liver failure, resulting in death or liver transplantation in more than one third of patients in the United States. The effectiveness of the only antidote, N-acetylcysteine, declines rapidly after APAP ingestion, long before patients are admitted to the clinic with symptoms of severe liver injury. The direct hepatotoxicity of APAP triggers a cascade of innate immune responses that may exacerbate or limit the progression of tissue damage. A better understanding of this complex mechanism will help uncover targets for therapeutic interventions. APPROACH AND RESULTS: We observed that APAP challenge caused stabilization of hypoxia-inducible factors (HIFs) in the liver and hepatic macrophages (MΦs), particularly HIF-2α. Genetic deletion of the HIF-2α gene in myeloid cells (HIF-2αmye/- ) markedly exacerbated APAP-induced liver injury (AILI) without affecting APAP bioactivation and detoxification. In contrast, hepatic and serum levels of the hepatoprotective cytokine interleukin 6 (IL-6), its downstream signal transducer and transcription factor 3 activation in hepatocytes, as well as hepatic MΦ IL-6 expression were markedly reduced in HIF-2αmye/- mice compared to wild-type mice post-APAP challenge. In vitro experiments revealed that hypoxia induced IL-6 production in hepatic MΦs and that such induction was abolished in HIF-2α-deleted hepatic MΦs. Restoration of IL-6 by administration of exogenous IL-6 ameliorated AILI in HIF-2αmye/- mice. Finally, IL-6-mediated hepatoprotection against AILI was abolished in hepatocyte-specific IL-6 receptor knockout mice. CONCLUSIONS: The data demonstrate that APAP treatment leads to HIF-2α stabilization in hepatic MΦs and that HIF-2α subsequently reprograms hepatic MΦs to produce the hepatoprotective cytokine IL-6, thereby ameliorating AILI.
BACKGROUND AND AIMS: Acetaminophen (APAP) overdose represents the most frequent cause of acute liver failure, resulting in death or liver transplantation in more than one third of patients in the United States. The effectiveness of the only antidote, N-acetylcysteine, declines rapidly after APAP ingestion, long before patients are admitted to the clinic with symptoms of severe liver injury. The direct hepatotoxicity of APAP triggers a cascade of innate immune responses that may exacerbate or limit the progression of tissue damage. A better understanding of this complex mechanism will help uncover targets for therapeutic interventions. APPROACH AND RESULTS: We observed that APAP challenge caused stabilization of hypoxia-inducible factors (HIFs) in the liver and hepatic macrophages (MΦs), particularly HIF-2α. Genetic deletion of the HIF-2α gene in myeloid cells (HIF-2αmye/- ) markedly exacerbated APAP-induced liver injury (AILI) without affecting APAP bioactivation and detoxification. In contrast, hepatic and serum levels of the hepatoprotective cytokine interleukin 6 (IL-6), its downstream signal transducer and transcription factor 3 activation in hepatocytes, as well as hepatic MΦ IL-6 expression were markedly reduced in HIF-2αmye/- mice compared to wild-type mice post-APAP challenge. In vitro experiments revealed that hypoxia induced IL-6 production in hepatic MΦs and that such induction was abolished in HIF-2α-deleted hepatic MΦs. Restoration of IL-6 by administration of exogenous IL-6 ameliorated AILI in HIF-2αmye/- mice. Finally, IL-6-mediated hepatoprotection against AILI was abolished in hepatocyte-specific IL-6 receptor knockout mice. CONCLUSIONS: The data demonstrate that APAP treatment leads to HIF-2α stabilization in hepatic MΦs and that HIF-2α subsequently reprograms hepatic MΦs to produce the hepatoprotective cytokine IL-6, thereby ameliorating AILI.
Authors: William Y Kim; Michal Safran; Marshall R M Buckley; Benjamin L Ebert; Jonathan Glickman; Marcus Bosenberg; Meredith Regan; William G Kaelin Journal: EMBO J Date: 2006-09-14 Impact factor: 11.598
Authors: M Ohh; C W Park; M Ivan; M A Hoffman; T Y Kim; L E Huang; N Pavletich; V Chau; W G Kaelin Journal: Nat Cell Biol Date: 2000-07 Impact factor: 28.824
Authors: Tzu-Lan Yeh; Thomas M Leissing; Martine I Abboud; Cyrille C Thinnes; Onur Atasoylu; James P Holt-Martyn; Dong Zhang; Anthony Tumber; Kerstin Lippl; Christopher T Lohans; Ivanhoe K H Leung; Helen Morcrette; Ian J Clifton; Timothy D W Claridge; Akane Kawamura; Emily Flashman; Xin Lu; Peter J Ratcliffe; Rasheduzzaman Chowdhury; Christopher W Pugh; Christopher J Schofield Journal: Chem Sci Date: 2017-09-11 Impact factor: 9.825
Authors: Ming Ni; Haoming Zhou; Jing Zhang; Dan Jin; Tianfei Lu; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Xuehao Wang; Yuan Zhai Journal: J Immunol Date: 2020-07-17 Impact factor: 5.422
Authors: Ming Ni; Jing Zhang; Rebecca Sosa; Hanwen Zhang; Han Wang; Dan Jin; Kaitlyn Crowley; Bita Naini; F Elaine Reed; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Xuehao Wang; Yuan Zhai Journal: Hepatology Date: 2021-08-10 Impact factor: 17.298